Polaryx Therapeutics, Inc. (PLYX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$1.38M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$1.96M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$884.00K; Depreciation and amortization (m).
- 2025-03-31: Basis Reported; EBITDA (m); Operating income -$5.05M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$1.38M | (m) | (m) | (m) | (m) | -$1.37M* | (m) | $719.00K | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$1.96M | (m) | (m) | (m) | (m) | -$2.06M | (m) | $679.00K | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$884.00K | (m) | (m) | (m) | (m) | -$858.00K* | (m) | $476.00K | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$5.05M | (m) | (m) | (m) | (m) | -$709.00K | (m) | $4.72M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$7.82M | (m) | (m) | (m) | (m) | -$3.94M | (m) | $6.27M | (m) | (m) |
| 2024-12-31 | Reported | (m) | -$4.35M | (m) | (m) | (m) | (m) | -$2.57M | (m) | $2.81M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |